Accendra Seeks 1-for-20 to 1-for-30 Reverse Split to Cure NYSE Delisting Notice
ACH is trading near its 52-week low of $0.197 (6.5% above the low) on elevated volume (2.9× avg).
Summary
Accendra Health filed a preliminary proxy asking shareholders to approve a 1-for-20 to 1-for-30 reverse stock split to regain NYSE compliance after its October 6 minimum-price notice. Approval is the company's main path to avoiding delisting.
Key Events · Corporate Governance and Compliance · ACH
-
Reverse Split Proposed to Cure NYSE Notice
Board seeks a 1-for-20 to 1-for-30 reverse split, final ratio at its discretion, plus a proportional cut in authorized shares from 200,000,000.
-
Delisting Risk If Vote Fails
The October 6, 2026 NYSE notice requires a $1.00 average closing price over 30 trading days; failure to cure leads to delisting proceedings and likely OTC trading.
-
One-Shot Cure Under NYSE Rules
NYSE rules bar another reverse split within 12 months to regain compliance, so a post-split price decline leaves no second split remedy.
-
Special Meeting and Record Date Set
Record date is October 27, 2026; the meeting date and time are left blank in this preliminary proxy, and the board may abandon the split even if approved.
Analysis · ACH · Trade & Services
Accendra is asking shareholders to approve a reverse split of 1-for-20 to 1-for-30 — the company's chosen route to get its share price back above the NYSE's $1.00 minimum after receiving a continued-listing notice on October 6, 2026. The split itself changes nothing about the business or anyone's proportional ownership, but the stakes are real: if shareholders vote it down and the price stays under $1.00, the NYSE begins delisting proceedings, which would push the stock to OTC markets, hurt liquidity, and make it harder to raise the capital the company needs. The board can still abandon the split even if approved, and NYSE rules bar a second reverse split within 12 months to cure the same problem — so this is effectively a one-shot fix. The special meeting date and record date (October 27, 2026) are still blank in this preliminary proxy.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACH was trading at $0.21 on NYSE in the Trade & Services sector, with a market capitalization of approximately $16.9M. The 52-week trading range was $0.20 to $5.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.